Response: Co-administration of cyclosporine A and imatinib among patients with Philadelphia chromosome-positive leukemias in the post-transplant setting

Eur J Clin Pharmacol. 2016 Dec;72(12):1539-1540. doi: 10.1007/s00228-016-2123-0. Epub 2016 Aug 25.

Authors

Ferdows Atiq¹, Annoek E C Broers², Louise M Andrews¹, Jeanette K Doorduijn², Birgit C P Koch¹, Teun Van Gelder^{1

3}, Jorie Versmissen⁴

Affiliations

¹ Department of Hospital Pharmacy, Erasmus Medical Center, Rotterdam, The Netherlands.
² Department of Hematology, Erasmus Medical Center, Rotterdam, The Netherlands.
³ Department of Internal Medicine, Erasmus Medical Center, PO Box 2040, 3000, CA, Rotterdam, The Netherlands.
⁴ Department of Internal Medicine, Erasmus Medical Center, PO Box 2040, 3000, CA, Rotterdam, The Netherlands. J.versmissen@erasmusmc.nl.

PMID: 27561268
DOI: 10.1007/s00228-016-2123-0

No abstract available

Publication types

Letter
Comment

MeSH terms

Antineoplastic Agents
Benzamides
Cyclosporine
Humans
Imatinib Mesylate*
Leukemia
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Philadelphia Chromosome*
Piperazines
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Pyrimidines

Substances

Antineoplastic Agents
Benzamides
Piperazines
Pyrimidines
Cyclosporine
Imatinib Mesylate